Expanded Patient Access: Balancing Risk and Reward

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 3744.

Product Description

The FDA allows for expanded access of drugs in development to dying patients who have no other options. New “Right-to-Try” laws, which now exist in 38 states, provide little to no patient protections.

FEEDBACK